Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats

Allergology International

Volumn 52, Issue 2, 2003, Pages 77-83

  Tamura, Tadafumi ^a   Sato, Hitoshi ^a   Miki, Ichiro ^a   Suzuki, Kazuo ^a   Ohmori, Kenji ^a   Karasawa, Akira ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Conjunctivitis; Olopatadine; Rats

Indexed keywords

ANTIBODY; CETIRIZINE; CHLORPHENIRAMINE; COMPOUND 48-80; CROMOGLYCATE DISODIUM; EBASTINE; EPINASTINE; EVANS BLUE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; OLOPATADINE; OVALBUMIN;

ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMOSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DOSE RESPONSE; HISTAMINE RELEASE; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0037501234     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2003.00281.x     Document Type: Article

References (22)

1. Katelaris CH. Allergic rhinoconjunctivitis: An overview. Acta Ophthalmol. Scand. Suppl. 2000; 230: 66-8.
2. 1-receptor antagonists. Clinical pharmacology and therapeutics. J. Allergy Clin. Immunol. 1989; 84: 845-61.
3. 1 receptor. Eur. J. Pharmacol. 1998; 12: 111-17.
4. 1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 1996; 12: 401-7.
5. Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn. J. Pharmacol. 2002; 88: 379-97.
6. Ikemura T, Manabe H, Sasaki Y et al. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int. Arch. Allergy Immunol. 1996; 110: 57-63.
7. Miyake K, Ohmori K, Ishii A, Karasawa A. Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils. Allergol. Int. 2001; 50: 113-16.
8. Ikemura T, Sasaki Y, Ishii H, Ohmori K. Inhibitory effect of KW-4679, an anti-allergic drug, on tachykininmediated airway response induced by electrical vagal stimulation in guinea pigs. Jpn. J. Pharmacol. 1996; 71: 179-82.
9. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFα release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. 2000; 84: 504-8.
10. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. 2001; 87: 424-9.
11. Stotland LM, Share NN. Active bronchial anaphylaxis in the rat. Can. J. Physiol. Pharmacol. 1974; 52: 1114-18.
12. Kamei C, Sugimoto Y, Nakamura S, Zhong C. Effect of (Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs. Arzneimittelforschung 1995; 45: 1005-8.
13. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic anti-allergic agent with dual activity. Am. J. Ophthalmol. 1998; 125: 797-804.
14. Artal MN, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol. Scand. Suppl. 2000; 230: 64-5.
15. Umemoto M, Tanaka H, Miichi H, Hayashi S. Histamine receptors on rat ocular surface. Ophthalmic Res. 1987; 19: 200-4.
16. Iso T, Nakajima N, Suda H, Yamauchi H, Uda K. Passive anaphylaxis in rat conjunctiva and topical effects of antiallergic agents. Ophthalmic Res. 1980; 12: 9-15.
17. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol. 1999; 117: 643-7.
18. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocul. Pharmacol. Ther. 1996; 12: 389-400.
19. Allansmith MR, Baird RS, Ross RN, Barney NP, Bloch KJ. Ocular anaphylaxis induced in the rat by topical application of compound 48/80. Dose-response and time course study. Acta Ophthalmol. Suppl. 1989; 192: 145-53.
20. Tiligada E, Aslanis D, Delitheos A, Varonos D. Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva. Pharmacol. Res. 2000; 41: 667-70.
21. Proud D, Sweet J, Stein P et al. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J. Allergy Clin. Immunol. 1990; 85: 896-905.
22. Fujishima H, Takeyama M, Takeuchi T, Saito I, Tsubota K. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis. Clin. Exp. Allergy 1997; 27: 372-8.